Targeting multiple key signaling pathways in melanoma using leelamine

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1679-1689

  Gowda, Raghavendra ^a   Madhunapantula, SubbaRao V ^a   Kuzu, Omer F ^a   Sharma, Arati ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LEELAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG; DITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL LINE; MOLECULAR LIBRARY; MOUSE; MTS ASSAY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DRUG EFFECTS; MELANOCYTE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; SKIN NEOPLASMS;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DITERPENES; FEMALE; HUMANS; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84904183203     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0867     Document Type: Article

References (50)

1. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012;24:150-4.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
3. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 2011;71:7137-40.
4. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-61.
5. Krasilnikov M, Ivanov VN, Dong J, Ronai Z. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003; 22:4092-101. (Pubitemid 36819649)
6. Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. Activated stat-3 in melanoma. Cancer Control 2008;15:196-201.
7. Madhunapantula SV, Robertson GP. Therapeutic implications of targeting AKT signaling in melanoma. Enzyme Res 2011;2011:327923.
8. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, et al. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006;66: 8200-9. (Pubitemid 44299188)
9. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10. (Pubitemid 39331010)
10. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96.
11. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73. (Pubitemid 30339202)
12. Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Dev 2009;12:189-96.
13. Altmann KH, Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007;24:327-57. (Pubitemid 46504987)
14. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009;325:161-5.
15. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005;100:72-9. (Pubitemid 41073525)
16. Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res 2009;59:365-78.
17. Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today 2008;13:161-71.
18. William AD, David S, Ntsang N, Zhao HS, David P, Duncan C, et al. Leelamine, a novel diterpene, exhibits potent cannabinoid-like effects in vivo. In:Obreza O, editor. 5th Joint Meeting on Med Chem; Slovenia; 2007.
19. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008;435-77.
20. Cadoudal T, Distel E, Durant S, Fouque F, Blouin JM, Collinet M, et al. Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue. Diabetes 2008;57:2272-9.
21. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, et al. Melanoma cell lines fromdifferent stages of progression and their biological and molecular analyses. Melanoma Res 1997;7 Suppl 2:S35-42. (Pubitemid 27501624)
22. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther 2012;13:756-65.
23. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008;68:7638-49.
24. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2881-90. (Pubitemid 36667160)
25. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, et al. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res 2009;15:1674-85.
26. Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol 2013;182:1151-62.
27. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005;24:315-27. (Pubitemid 40922802)
28. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, et al. Clinical cancer advances 2012: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2013;31:131-61.
29. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. J Clin Oncol 2012;30:2912-8.
30. Flaherty KT, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res 2011;17:4922-8.
31. Oliveria SA, Hay JL, Geller AC, Heneghan MK, McCabe MS, Halpern AC. Melanoma survivorship: research opportunities. J Cancer Surviv 2007;1:87-97.
32. Smalley KS, McArthur GA. The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol 2012;39:204-14.
33. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
34. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
35. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468: 968-72.
36. Wang AX, Qi XY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life 2013;65:748-58.
37. Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012;10:23.
38. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
39. Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012;72:430-9.
40. Wu S, Singh RK. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr Mol Med 2011;11:553-63.
41. Flaherty KT. Throwing the kitchen sink at melanoma drug development. Pigment Cell Melanoma Res 2012;5:543-4.
42. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 2008; 68:5-8. (Pubitemid 351380097)
43. Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009;22:400-19.
44. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 2007;67: 3626-36. (Pubitemid 46762147)
45. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012;72:969-78.
46. Sakaguchi M, Oka M, Iwasaki T, Fukami Y, Nishigori C. Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells. J Invest Dermatol 2012;132:1877-85.
47. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008;68:3429-39.
48. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 2010;80:624-37.
49. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012;18:33-9.
50. Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, et al. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004;64:2552-60. (Pubitemid 38523912)